These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1210 related items for PubMed ID: 27469583

  • 1. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators.
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [Abstract] [Full Text] [Related]

  • 2. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
    Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP.
    Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [Abstract] [Full Text] [Related]

  • 5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A, RELIEF investigators.
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [Abstract] [Full Text] [Related]

  • 6. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S.
    Arthritis Res Ther; 2016 Dec 30; 18(1):305. PubMed ID: 28038680
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.
    Arthritis Rheumatol; 2017 Jul 30; 69(7):1451-1460. PubMed ID: 28376288
    [Abstract] [Full Text] [Related]

  • 8. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM, SLS I and SLS II study groups.
    Ann Rheum Dis; 2019 Jan 30; 78(1):122-130. PubMed ID: 30409830
    [Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group.
    N Engl J Med; 2006 Jun 22; 354(25):2655-66. PubMed ID: 16790698
    [Abstract] [Full Text] [Related]

  • 10. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
    Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL, RECITAL Investigators.
    Lancet Respir Med; 2023 Jan 22; 11(1):45-54. PubMed ID: 36375479
    [Abstract] [Full Text] [Related]

  • 11. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK, Sharma SK, Adarsh MB, Dhir V, Sinha A, Dhooria S, Jain S.
    Rheumatol Int; 2020 Feb 22; 40(2):207-216. PubMed ID: 31813058
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN.
    Cochrane Database Syst Rev; 2018 Jan 03; 1(1):CD010908. PubMed ID: 29297205
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
    Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP.
    Lung; 2013 Oct 03; 191(5):483-9. PubMed ID: 23925736
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D, Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group.
    Arthritis Care Res (Hoboken); 2018 Mar 03; 70(3):439-444. PubMed ID: 28544580
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T, Sakagami T, Kikuchi T, Takada T.
    Respir Investig; 2018 Jan 03; 56(1):14-20. PubMed ID: 29325675
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.
    Clin Exp Rheumatol; 2016 Jan 03; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
    Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.
    Lancet Haematol; 2019 Mar 03; 6(3):e132-e143. PubMed ID: 30824040
    [Abstract] [Full Text] [Related]

  • 20. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
    Int J Rheum Dis; 2014 Nov 03; 17(8):923-8. PubMed ID: 24864029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.